8-K: Health In Tech: Leadership Shift Amidst Revenue Dip

Health In Tech announces a CEO transition and discusses Q3 2026 results, highlighting strategic investments in new platforms like HitRix and HITChain, while facing revenue declines and increased operating expenses.

Summary

• Health In Tech (HIT) held an earnings call on November 12, 2026, to discuss its Q3 2026 financial and operating results.
• A significant leadership transition occurred with Tim Johnson stepping down as CEO to become Executive Chairman, and Sanjay Shrestha appointed as the new CEO.
• The company is focusing on translating its technological foundation into scalable commercial growth and improved financial performance.
• 2026 has been a year of investment in sales, distribution, and technology, including initiatives like HitRix (AI-powered large-group insurance marketplace) and HITChain (blockchain for claims administration).
• The company acknowledges that product commercialization and bringing new products to market have taken longer than anticipated, impacting near-term financial contributions.
• As of October 30, 2026, the company had approximately $150 million in potential annualized revenue from quoting activity for policies with anticipated effective dates in November 2026, December 2026, and January 2027.
• Total revenue for Q3 2026 was $6.6 million, down from $8.5 million in the prior year, and for the first nine months of 2026 was $23.4 million, down from $25.8 million.
• Adjusted EBITDA for Q3 2026 was negative $3.9 million, compared to positive $1.0 million in the prior year, and net loss for the quarter was $7.1 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously negative sentiment due to declining revenues, increased expenses, and a net loss, despite strategic initiatives and leadership changes aimed at future growth.

Positives

• The company has built a strong technological foundation and developed meaningful industry relationships.
• The distribution network continues to expand, with 984 distribution partners by the end of Q3 2026, a 15.9% year-over-year increase.
• Operating cash flow has shown sequential improvement, with a 68% reduction in burn from Q1 to Q3 2026.
• The company ended the quarter with $10.1 million in cash and cash equivalents, an increase from $7.7 million at the end of 2025.
• The Three-Year Rate Stabilization Program aims to provide employers with greater predictability in healthcare insurance costs.
• HitRix, an AI-powered platform, is designed to modernize the quoting, underwriting, and placement process for large employer health plans.
• HITChain aims to transform healthcare claims administration using blockchain and AI for improved speed and transparency.
• The company has secured its initial client under a medical stop-loss agreement for the Three-Year Rate Stabilization Program.

Negatives

• Total revenue for Q3 2026 decreased to $6.6 million from $8.5 million in the prior year.
• Revenue for the first nine months of 2026 was $23.4 million, down from $25.8 million in the prior year.
• Gross margin decreased to 46.5% in Q3 2026 from 60.6% a year ago, and to 49.1% for the first nine months from 65.1%.
• Adjusted EBITDA for Q3 2026 was negative $3.9 million, compared to positive $1.0 million in the prior year.
• Net loss for Q3 2026 was $7.1 million, compared to a net income of $0.5 million in the prior year.
• Operating expenses increased significantly in Q3 2026 to $11.5 million from $4.7 million a year ago, largely due to a $5.3 million provision charge.
• The company acknowledges that certain initiatives have taken longer than anticipated, pushing back financial contributions.
• The underwriting modeling revenue (ICE subsidiary) declined sharply to $3.37 million for the first nine months of 2026 from $5.83 million a year ago.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.
• The company's actual results could be affected by risks detailed in its SEC filings, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
• The conversion of pipeline revenue to contracted revenue depends on underwriting, pricing, broker and employer decisions, carrier capacity, and successful policy placement.
• The timing and ultimate conversion of opportunities for the Three-Year Rate Stabilization Program depend on underwriting, contractual, financing, and execution requirements.
• The launch of the HitRix MVP in Q1 2027 and its subsequent commercial adoption are subject to execution risks.
• The launch of the HITChain MVP in the second half of 2027 is dependent on validating technology and establishing ecosystem relationships.
• The company's ability to translate investments into customer adoption, transaction volume, revenue growth, and improved financial performance is a key risk.
• The company faces risks related to coordinating multiple participants for new product launches and potential delays in product commercialization.

Future Outlook

The company updated its full-year 2026 revenue outlook to approximately $30 million. For 2027, the company believes its new initiatives will make a more meaningful contribution, but a finalized 2027 plan is still under review. The focus will be on scaling HitRix, advancing HITChain, expanding distribution, and evaluating strategic growth opportunities, while reaccelerating the existing business.

Management Comments

• "We believe Health In Tech has built a strong foundation. Our key focus and strategic priority is to translate that foundation into scalable commercial growth and stronger financial performance."
• "We recognize that certain initiatives have taken longer than originally anticipated. Product commercialization has required more time. Bringing additional carrier capacity online has taken longer than expected."
• "I want to be clear: we are not satisfied with our current revenue performance. Investment is necessary, but investment alone does not create value for all stakeholders."
• "My first priority is to be laser focused on re-accelerating our core business to improve outcomes for all stakeholders..."
• "Our objective is not growth for its own sake. It is to build a business capable of generating sustainable growth, improving profitability, and delivering attractive returns on invested capital."
• "We are not satisfied with weaker revenue and higher expenses. We believe in the opportunity, but the responsibility to turn that opportunity into results is ours."

Industry Context

StockSavvy.ai notes that Health In Tech operates in the highly competitive and rapidly evolving health insurance technology sector. The company's focus on AI, blockchain, and marketplace solutions aligns with broader industry trends towards digitalization, efficiency, and data-driven decision-making. However, the challenges in commercialization and revenue growth highlight the difficulty in disrupting established markets and the significant investment required.

Comparison to Industry Standards

• The company's gross margin target of 45%-50% is within a typical range for technology-enabled service providers, but the recent decline from over 60% suggests a shift in business mix or increased service costs.
• The significant increase in operating expenses, particularly the provision for credit losses, is a notable deviation from prior periods and warrants close monitoring.
• The focus on AI and blockchain for claims administration and marketplace solutions reflects innovation seen in other insurtech companies aiming to reduce administrative overhead and improve customer experience.
• The company's distribution partner growth of 15.9% is a positive indicator, suggesting traction in building its network, which is crucial for market penetration in the insurance sector.

Management Changes

Stakeholder Impact

• Shareholders: The leadership transition and focus on execution aim to create long-term shareholder value, but current financial performance and delays present near-term concerns.
• Employees: The company is investing in sales and technology capabilities, suggesting a focus on growth and potentially new opportunities, but also acknowledging workforce optimization initiatives.
• Partners (Brokers, Carriers, MGUs, TPAs): The company is emphasizing stronger collaboration, improved coordination, and providing new tools (HitRix) to facilitate business and potentially increase transaction volumes.
• Clients (Employers): The Three-Year Rate Stabilization Program aims to provide greater predictability and budget certainty for healthcare insurance costs.

Next Steps

• Focus on converting qualified opportunities into bound policies and recognized revenue.
• Work more proactively with brokers, distribution partners, carriers, and MGUs to resolve obstacles.
• Implement active pipeline management, stronger follow-through, improved coordination, and accountability.
• Complete the first end-to-end launch of the Three-Year Rate Stabilization Program by the end of 2026.
• Launch the minimum viable product (MVP) for HitRix in the first quarter of 2027.
• Launch an initial MVP for HITChain during the second half of 2027.
• Strengthen operational discipline and financial performance, focusing on capital allocation and return on investment.
• Conduct a comprehensive review of 2027 priorities and capital decisions under new CEO Sanjay Shrestha.

Key Dates

Recommendation

The company is undergoing a significant leadership transition and is investing heavily in new platforms (HitRix, HITChain) and programs (Three-Year Rate Stabilization) for future growth. However, current financial results show declining revenue, increased expenses, and a net loss. While there are positive signs in distribution growth and improving cash flow, the delays in commercialization and the need to prove the financial viability of new initiatives warrant a cautious 'hold' until clearer execution and revenue growth are demonstrated.

Keywords

Health Insurance, Insurtech, AI, Blockchain, Marketplace, Claims Administration, Underwriting, Commercialization